Vice President
Revolution Medicines
Vice President
Revolution Medicines
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
The Vice President, Portfolio Chemistry will report to the Senior Vice President, Medicinal Chemistry and Screening Sciences, and lead Revolution Medicines' multidisciplinary Portfolio Chemistry organization, with responsibility for Medicinal Chemistry and chemistry leadership across the discovery portfolio. This executive will provide strategic and scientific leadership for the advancement of oncology programs from validated hit series through development candidate nomination.
Working at the intersection of chemistry, biology, structural sciences, computational chemistry, and translational research, the VP will be accountable for portfolio chemistry outcomes and delivery of high-quality development candidates while driving operational excellence, scientific innovation, and organizational performance across the portfolio. In this role, VP of Portfolio Chemistry will integrate modern medicinal chemistry strategies, with AI-enabled drug discovery and predictive analytics tools.
Working closely with the Vice President, Early Discovery Chemistry, this leader will ensure seamless transition of differentiated chemical matter into lead optimization while maintaining clear accountability for candidate delivery.
Key responsibilities will include:
Partner with Research leadership to define and execute a long-term strategy for expanding the portfolio through advancement of novel small-molecule therapeutics.
Develop and execute the chemistry strategy supporting advancement of Revolution Medicines' discovery portfolio from hit validation through development candidate nomination.
Partner with the VP, Early Discovery Chemistry to establish clear criteria and ensure effective transitions from hit identification/validation into portfolio medicinal chemistry.
Drive integration of chemistry with computational chemistry, digital drug discovery, AI/ML technologies, and data science capabilities across discovery workflows.
Lead organizational planning, internal and external resource allocation (CRO management), talent strategy, and capability development across multiple functions.
Partner with Research Leadership to prioritize resources and maximize portfolio value.
Drive alignment across Research functions to support a dynamic portfolio of discovery and development-stage programs.
Vision, strategy, leadership: Partner with Research Leadership to translate portfolio strategy into differentiated chemistry programs and ensure effective advancement of the highest-value opportunities. Establish and maintain exceptional chemistry project leadership across the portfolio, developing capable project leaders.
Innovation: Champion predictive analytics, AI/ML methodologies, and computational approaches that increase throughput and accelerate DMTA cycles.
Management excellence: Manage a high-performing group, sustain productivity through strategic hiring, mentoring, and support for individual career growth. Be accountable for an annual budget.
Cross-functional collaboration: Position the MedChem function as a bridge across Research, enabling bench-to-bedside insights. Serve as a visible leader representing Revolution Medicines’ scientific excellence internally and externally.
Required Skills, Experience and Education:
Ph.D. in Organic Chemistry.
Minimum 16+ years of industrial drug discovery experience with extensive medicinal chemistry leadership.
Demonstrated success advancing multiple programs from hit validation through development candidate nomination and ideally IND-enabling studies.
Proven leadership of multidisciplinary chemistry organizations supporting multiple concurrent discovery programs.
Deep expertise in medicinal chemistry, structure-based drug design, optimization strategies, and candidate selection.
Experience integrating computational chemistry, AI/ML technologies, and digital drug discovery into medicinal chemistry workflows.
Strong experience managing external collaborations, CROs, and strategic partnerships.
Outstanding leadership, communication, and organizational development skills.
Demonstrated ability to build, lead, and foster a collaborative culture on interdisciplinary teams.
Preferred Skills:
Experience in oncology drug discovery.
Experience of successful IND filings and clinical candidate delivery.
Record of scientific publications, patents, and invited presentations.
Experience with alternative modality, ex. molecular glue and ADC drug discovery.
#LI-SB1 #LI-ONSITE
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Base Pay Salary Range 294000 - 367000 USD
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.
Explore more opportunities at Revolution Medicines